Hospital de Clínicas de Porto Alegre-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2024

  1. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Journal of Hepatology

2023

  1. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

    Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

2020

  1. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

    Liver International, Vol. 40, Núm. 6, pp. 1467-1476